cancer is considered as a challenging deathly disease and discovering or synthesis of new cytotoxic agents is a worldwide attempt. in this study, a group of recently synthesized chalcones, with the structure of 1,3-diarylprop-2-en-1-one having differesnt cox-1 and/or cox-2 selectivities, have been examined on human hepatocarcinoma (hepg2), lung carcinoma (a549), and breast adenocarcinoma (mcf-7...

BACKGROUND In clinical trials, cyclooxygenase (COX)-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs) were associated with an increased risk of thromboembolic events. We studied the association between NSAID use and risk of stroke in the prospective, population-based Rotterdam Study. METHODS We followed 7636 persons free of stroke at baseline (1991-1993) for incident stroke until Sept...

introduction: ketoprofen is an nsaid and selective cox-1 inhibitor. in our previous study the role of flunixin meglumine, a nonselective cox inhibitor was studied on seizure and its anticonvulsant effects were confirmed. therefore this research is performed to assess the role of a selective cox-1 inhibitor, ketoprofen in treatment of seizures induced by ptz. methods: in this research, male wist...

OBJECTIVE Virtual molecular dynamic sesquiterpenoid Pogostemon Herba (CID56928117, CID94275, CID107152, and CID519743) have screening as cyclooxygenase (COX-1/COX-2) selective inhibitor. METHODS Molecular interaction studies sesquiterpenoid compounds with COX-1 and COX-2 were using the molecular docking tools by Hex 8.0 and interactions were further visualized using by Discovery Studio Client...

Compounds combining dual inhibitory action against FAAH and cyclooxygenase (COX) may be potentially useful analgesics. Here, we describe a novel flurbiprofen analogue, N-(3-bromopyridin-2-yl)-2-(2-fluoro-(1,1'-biphenyl)-4-yl)propanamide (Flu-AM4). The compound is competitive, reversible inhibitor of with Ki value 13 nM which inhibits COX activity in substrate-selective manner. Molecular modelli...